Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

This study is currently recruiting patients.

Sponsored by:	National Cancer Institute (NCI)
Information provided:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00575770
Condition	Malignant Mesothelioma
Intervention	Drug: SS1(dsFv)-PE38 immunotoxin Drug: cisplatin Drug: pemetrexed disodium Procedure: chemotherapy Procedure: immunoenzyme technique Procedure: immunohistochemistry staining method Procedure: immunotoxin therapy Procedure: pharmacological study Procedure: quality-of-life assessment
Phase	Phase 1

Purpose:

This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.

RATIONALE: Immunotoxins can find tumor cells and kill them without harming normal cells. Drugs used in chemotherapy, such as pemetrexed and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with immunotoxin therapy may kill more malignant mesothelioma cells.

Eligibility

Study Design: Treatment, Non-Randomized, Open Label, Active Control

Official Title: A Phase I, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma

Enrollment Size: Both

Gender: 18 Years

Min. Age: N/A

Max. Age:

Location and Contact Information

United States, Maryland
Warren Grant Magnuson Clinical Center – NCI Clinical Trials Referral Office, Bethesda, Maryland, 20892-1182, United States
Status: Recruiting
Clinical Trials Office – Warren Grant Magnusen Clinical Center 888-NCI-1937

Actively Recruiting:

The following is a list of clinial trials currently in process in the search for the treament and cure of mesotheilioma. If you are a mesotheilioma patient, please contact your doctor for more information about these trials.

Trial: Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients

Conditions: Mesothelioma

Trial: Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

Conditions: Malignant Mesothelioma

Trial: Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Conditions: Lung Cancer; Mesothelioma

Trial: Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Conditions: Malignant Mesothelioma

Trial: Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Conditions: Malignant Mesothelioma

Trial: Tomotherapy Treatment for Mesothelioma

Conditions: Mesothelioma